Search research articles
Contact Us
Filters
Showing results (1-10 of 55) with videos related to
Page
of 6
Sort By:
Canadian Journal of Diabetes
|
September 26, 2017
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Julie A Lovshin
Canadian Journal of Diabetes
|
April 11, 2017
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Julie A Lovshin
Canadian Journal of Diabetes
|
October 7, 2014
Blood pressure-lowering effects of incretin-based diabetes therapies
Julie A Lovshin, Bernard Zinman
Nature Reviews. Endocrinology
|
September 18, 2013
Diabetes: Clinical inertia--a barrier to effective management of T2DM
Julie A Lovshin, Bernard Zinman
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|
October 28, 2017
Les « nouvelles » classes d'antidiabétiques: Considérations ophtalmologiques relatives aux agonistes du GLP-1R, aux inhibiteurs de la DPP-4 et aux inhibiteurs du SGLT2
Kylen D McReelis, Julie A Lovshin
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie
|
November 22, 2017
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting
Sharon C Peacock, Julie A Lovshin
Nature Medicine
|
October 9, 2013
Metabolic disease puts up a fight: are diet and exercise helpful for the heart?
Julie A Lovshin, Daniel J Drucker
Nature Reviews. Nephrology
|
December 24, 2018
Sodium transport in diabetes: two sides to the coin
Julie A Lovshin, David Z Cherney
Journal of Diabetes and Its Complications
|
February 2, 2017
Inadequate screening for retinopathy among recent immigrants with type 2 diabetes despite universal health care: A population-based study
Julie A Lovshin, Baiju R Shah
Nature Reviews. Endocrinology
|
May 16, 2009
Incretin-based therapies for type 2 diabetes mellitus
Julie A Lovshin, Daniel J Drucker
Page
of 6
Search research articles
Search
Showing results (1-10 of 55) with videos related to
Sort By:
Page
of 6
Canadian Journal of Diabetes
|
September 26, 2017
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Julie A Lovshin
Canadian Journal of Diabetes
|
April 11, 2017
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Julie A Lovshin
Canadian Journal of Diabetes
|
October 7, 2014
Blood pressure-lowering effects of incretin-based diabetes therapies
Julie A Lovshin, Bernard Zinman
Nature Reviews. Endocrinology
|
September 18, 2013
Diabetes: Clinical inertia--a barrier to effective management of T2DM
Julie A Lovshin, Bernard Zinman
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|
October 28, 2017
Les « nouvelles » classes d'antidiabétiques: Considérations ophtalmologiques relatives aux agonistes du GLP-1R, aux inhibiteurs de la DPP-4 et aux inhibiteurs du SGLT2
Kylen D McReelis, Julie A Lovshin
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie
|
November 22, 2017
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting
Sharon C Peacock, Julie A Lovshin
Nature Medicine
|
October 9, 2013
Metabolic disease puts up a fight: are diet and exercise helpful for the heart?
Julie A Lovshin, Daniel J Drucker
Nature Reviews. Nephrology
|
December 24, 2018
Sodium transport in diabetes: two sides to the coin
Julie A Lovshin, David Z Cherney
Journal of Diabetes and Its Complications
|
February 2, 2017
Inadequate screening for retinopathy among recent immigrants with type 2 diabetes despite universal health care: A population-based study
Julie A Lovshin, Baiju R Shah
Nature Reviews. Endocrinology
|
May 16, 2009
Incretin-based therapies for type 2 diabetes mellitus
Julie A Lovshin, Daniel J Drucker
Page
of 6